Search clinical trials for: Linagliptin 5mg

Total 12932 results

Boehringer Ingelheim
Eli Lilly and Company

Completed

30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks

Diabetes Mellitus, Type 2

United States, Estonia, Germany, Latvia, Spain, United Kingdom
Boehringer Ingelheim

Completed

The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients

Diabetes Mellitus, Type 2

Germany
Dong Wha Pharmaceutical Co. Ltd.

Completed

the Pharmacokinetic Profiles of Linagliptin With DW1029M (PLID)

Healthy

Korea, Republic of
GlaxoSmithKline

Completed

A Study in Asthmatics to Determine the Efficacy and Dose Response of Repeat Doses of GW870086X on Forced Expiratory Volume in 1 Second (FEV1)

Asthma

Germany, South Africa, Bulgaria
J2H Biotech

Completed

Phase 1 Study to Investigate Safety, Tolerability, PK/PK of J2H-1702 in Healthy Males

Non-alcoholic Steatohepatitis

Korea, Republic of
University of Edinburgh
NHS Lothian

Completed

Cardiovascular Effects of Apelin In Healthy Volunteers

Healthy

United Kingdom
GC Biopharma Corp

Recruiting

A Study to Evaluate the Safety, PK of GC2129A in Healthy Volunteers Under Fed Conditions

Healthy Volunteers

Korea, Republic of
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Linagliptin/Metformin Compared With Single Tablets

Healthy

United States
GC Biopharma Corp

Recruiting

A Study to Evaluate the Safety, PK of GC2129A in Healthy Volunteers Under Fasting Conditions

Healthy Volunteers

Korea, Republic of
Boehringer Ingelheim

Completed

Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM

Diabetes Mellitus, Type 2

United States, Argentina, Austria, Belgium, Canada, China, Croatia, Czech Republic, Finland, Germany, Greece, Hungary, India, Israel, Italy, Japan, Korea, Republic of, Malaysia, Mexico, Netherlands, New Zealand, Philippines, Poland, R... and more
JW Pharmaceutical

Completed

MAGE of Anagliptin Compared With Sitagliptin With Type 2 Diabetes Mellitus (ACACIA)

Type 2 Diabetes

Korea, Republic of
GlaxoSmithKline

Completed

A Study of GSK256073 in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin

Diabetes Mellitus, Type 2

Spain, United Kingdom, United States, France
Genor Biopharma Co., Ltd.

Unknown

Phase Ⅰ Clinical Trial of Gerilimzumab Injection in Healthy Subjects

Rheumatoid Arthritis

China
Universidad de Guanajuato
Hospital Regional de Alta Especialidad del Bajio

Completed

Linagliptin in Post-renal Transplantation

Transplanted Kidney Complication
Boehringer Ingelheim

Completed

Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Bulgaria, Denmark, France, Germany, Hong Kong, Hungary, India, Ireland, Italy, Netherlands, Norway, Poland, South Africa, Sweden, United Kingdom
Hanmi Pharmaceutical Company Limited

Completed

Duration of P-glycoprotein Inhibition After Oral Administration of HM30181AK Tablet (PGP inhibitor)

Healthy

Korea, Republic of
Merck Sharp & Dohme LLC

Completed

Dose Response Finding Study of MK-0431/ONO-5435 in Japanese Subjects With Impaired Glucose Tolerance (MK-0431-105)

Glucose Intolerance
Boehringer Ingelheim
Eli Lilly and Company

Completed

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
Institut de Recherches Internationales Servier

Completed

Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms

Alzheimer's Disease

Brazil, South Africa, Chile, Hungary, Bulgaria, Czechia, Germany, Japan, Mexico, Poland, Russian Federation, Slovakia
Ascletis Pharmaceuticals Co., Ltd.

Completed

Study to Evaluate the Safety and Efficacy of ASC40 in Subjects With Moderate to Severe Acne Vulgaris

Acne Vulgaris

China
Merck Sharp & Dohme LLC

Completed

Bioequivalence Study of Sitagliptin/Metformin Combination Tablet (MK0431A-122)

Type 2 Diabetes
Pfizer

Completed

A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia

Schizophrenia

United States
Helixmith Co., Ltd.

Completed

Safety Study of Gene Therapy in Treating Lower Leg Ischemia

Critical Limb Ischemia

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin

Diabetes Mellitus, Type 2

Germany, Spain, United States, Canada, Taiwan, Korea, Republic of, Finland, Denmark, France, Japan, Philippines, Vietnam
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin China Pharmaceutical Co., LTD.

Completed

Pharmacokinetic Study of KHK7580 in Healthy Adult Volunteers

Healthy Volunteer

China
The Wistar Institute
National Institute of Allergy and Infectious Diseases (NIAID); Merck Sharp... and other collaborators

Unknown

Reducing Proviral HIV DNA With Interferon-a (BEAT-HIV)

HIV/AIDS | HIV

United States
Merck Sharp & Dohme LLC

Completed

A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Concomitant Administration of Sitagliptin and Metformin as Individual Tablets (0431A-048)

Type 2 Diabetes
Merck Sharp & Dohme LLC

Completed

A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Co-administration of Sitagliptin and Metformin as Individual Tablets (0431A-095)

Type 2 Diabetes
JW Pharmaceutical

Completed

Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone (CWP-DIANA-302)

Type 2 Diabetes Mellitus

Korea, Republic of
Boehringer Ingelheim

Completed

Dose Proportionality of Different Dose Strengths of Linagliptin Tablets After Oral Administration to Healthy Male and Female Volunteers

Healthy
TWi Biotechnology, Inc.

Completed

Study of AC-201 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States, Taiwan
Otsuka Pharmaceutical Co., Ltd.

Recruiting

A Dose-ranging Trial of OPC-131461 in Cardiac Edema (Congestive Heart Failure [CHF])

Cardiac Edema (CHF)

Japan
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of TQ-F3083 Capsules in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

China
Johns Hopkins University
Cultivate Biologics

Completed

The Pharmacokinetics and Pharmacodynamics of a Single Acute Dose of a Hemp-derived Oral Product With a 1:1 Ratio of CBD:CBD-A

Cannabis

United States
Can-Fite BioPharma

Completed

Safety and Efficacy Study of CF101 to Treat Psoriasis

Plaque Psoriasis

Israel
Boehringer Ingelheim
Eli Lilly and Company

Completed

Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
GlaxoSmithKline

Completed

A Comparison of Atorvastatin and Glimepiride Fixed Dose Combination and Atorvastatin and Glimepiride Loose Combination in the Treatment of Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Korea, Republic of, Malaysia, Philippines, Thailand, Russian Federation, Mexico
Boehringer Ingelheim
Eli Lilly and Company

Completed

Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients

Diabetes Mellitus, Type 2

China, Malaysia, Philippines, Vietnam
GlaxoSmithKline

Withdrawn

GSK2190915 Pediatric Study

Asthma
Haisco Pharmaceutical Group Co., Ltd.

Completed

Relative Bioavailability and Pharmacodynamics of HSK7653 in Healthy Volunteers

Healthy

China
Boehringer Ingelheim

Completed

Relative Bioavailability of Two Fixed Dose Combination Tablets of Linagliptin/Pioglitazone Compared With Single Linagliptin and Pioglitazone Tablets Administered Together to Healthy Male and Female Subjects

Healthy
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT) (SUSTAIN)

Diabetes Mellitus, Type 2 | Diabetes

Taiwan, Korea, Republic of, South Africa, Hong Kong, Brazil, China, Ukraine
Sichuan Haisco Pharmaceutical Group Co., Ltd

Completed

HSK7653 Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

China
Alexandria University

Recruiting

Cognitive Protective Effect of Newer Antidiabetic Drugs

Type 2 Diabetes

Egypt
Sadat City University
Beni-Suef University

Completed

Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients?

Diabete Type 2

Egypt
Seung Up Kim

Active, not recruiting

Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Hepatitis B, Chronic | Fibrosis, Liver

Korea, Republic of
International Bio service

Not yet recruiting

The Bioequivalence Study of Linagliptin 5 mg Film-coated Tablet in Healthy Thai Volunteers

Healthy Volunteer
Boehringer Ingelheim

Completed

Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone

Diabetes Mellitus, Type 2

Austria, Greece, Hungary, Japan, Portugal, Romania, Spain
Merck Sharp & Dohme LLC

Completed

Initial Combination With Pioglitazone Study (0431-064)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)

Type 2 Diabetes Mellitus

3

Subscribe